• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Obesity

Novo Nordisk
Pharma

Novo Nordisk to reduce supply of Victoza to make more Ozempic

To address shortages for its weight loss products, Novo Nordisk is reducing production of diabetes drug Victoza to make more Ozempic.
Kevin Dunleavy Nov 22, 2023 10:55am
Novo Nordisk Ozempic

Export of Novo Nordisk's Ozempic could be banned in Germany

Nov 15, 2023 11:07am
boxing

UPDATED: Novo serves Lilly with obesity head-to-head trial

Nov 15, 2023 10:55am
Wegovy

Novo Nordisk touts Wegovy's value for heart disease patients

Nov 13, 2023 10:31am
Lilly

Eli Lilly's new obesity drug name tests well

Nov 10, 2023 8:36am
Eli Lilly

With FDA nod, Lilly's weight loss drug Zepbound has arrived

Nov 8, 2023 1:53pm

Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2023 Questex LLC All rights reserved.
Terms of use
Privacy Policy